Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants

被引：24
|
作者：
Vogel, AM
Lennon, DR
Broadbent, R
Byrnes, CA
Grimwood, K
Mildenhall, L
Richardson, V
Rowley, S
机构：
[1] Univ Auckland, Wellington, New Zealand
[2] Paediat Soc New Zealand, Infect Dis & Immunisat Comm, Wellington, New Zealand
[3] Paediat Soc New Zealand, Fetus & Newborn Comm, Wellington, New Zealand
[4] Paediat Soc New Zealand, Resp Comm, Wellington, New Zealand
来源：
JOURNAL OF PAEDIATRICS AND CHILD HEALTH | 2002年 / 38卷 / 06期
关键词：
consensus; cost effectiveness; palivizumab; preterm; respiratory syncytial virus;
D O I：
10.1046/j.1440-1754.2002.00057.x
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
Palivizumab prophylaxis significantly reduces hospitalization for respiratory syncytial virus (RSV) disease in preterm infants. However, palivizumab is very expensive. Data from a New Zealand cost-effectiveness analysis were considered by representatives of the Infectious Diseases and Immunisation, Fetus and Newborn, and Respiratory Committees of the Paediatric Society of New Zealand. Prophylaxis in all high-risk groups was associated with net cost. The consensus panel recommends that the priority for palivizumab be given to babies discharged on home oxygen with chronic lung disease, followed by babies born at 28 weeks or less gestation.
引用
收藏
页码：550 / 554
页数：5
相关论文
共 50 条
  • [11] Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion
    Meissner, HC
    Welliver, RC
    Chartrand, SA
    Law, BJ
    Weisman, LE
    Dorkin, HL
    Rodriguez, WJ
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1999, 18 (03) : 223 - 231
  • [12] Survey of pediatric ward hospitalization due to respiratory syncytial virus infection after the introduction of palivizumab to high-risk infants in Japan
    Kusuda, Satoshi
    Takahashi, Naoto
    Saitoh, Takami
    Terai, Masaru
    Kaneda, Hisashi
    Kato, Yuichi
    Ohashi, Atsushi
    Watabe, Shinichi
    Joh-o, Kunitaka
    Hirai, Katsuki
    PEDIATRICS INTERNATIONAL, 2011, 53 (03) : 368 - 373
  • [13] Cost Effectiveness of Palivizumab for Respiratory Syncytial Virus Prophylaxis in High-Risk ChildrenA UK Analysis
    Mark J. C. Nuijten
    Wolfgang Wittenberg
    Maximilian Lebmeier
    PharmacoEconomics, 2007, 25 : 55 - 71
  • [14] Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection
    Brady, Michael T.
    Byington, Carrie L.
    Davies, H. Dele
    Edwards, Kathryn M.
    Jackson, Mary Anne
    Maldonado, Yvonne A.
    Murray, Dennis L.
    Orenstein, Walter A.
    Rathore, Mobeen H.
    Sawyer, Mark H.
    Schutze, Gordon E.
    Willoughby, Rodney E.
    Zaoutis, Theoklis E.
    Ralston, Shawn L.
    Lieberthal, Allan S.
    Meissner, H. Cody
    Alverson, Brian K.
    Baley, Jill E.
    Gadomski, Anne M.
    Johnson, David W.
    Light, Michael J.
    PEDIATRICS, 2014, 134 (02) : E620 - E638
  • [15] Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants
    Forbes, Michael L.
    Kumar, Veena R.
    Yogev, Ram
    Wu, Xionghua
    Robbie, Gabriel J.
    Ambrose, Christopher S.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (10) : 2789 - 2794
  • [16] One-year observational study of palivizumab prophylaxis on infants at risk for respiratory syncytial virus infection in Latin America
    Martin Castillo, Leandro
    Bugarin, Gabriela
    Carlos Arias, Juan
    Barajas Rangel, Jairo Israel
    Elina Serra, Maria
    Vain, Nestor
    JORNAL DE PEDIATRIA, 2017, 93 (05) : 467 - 474
  • [17] Respiratory illness and respiratory syncytial virus hospitalization in infants with a tracheostomy following prophylaxis with palivizumab
    Bosco Paes
    Mahwesh Saleem
    Doyoung Kim
    Krista L. Lanctôt
    Ian Mitchell
    European Journal of Clinical Microbiology & Infectious Diseases, 2019, 38 : 1561 - 1568
  • [18] Respiratory illness and respiratory syncytial virus hospitalization in infants with a tracheostomy following prophylaxis with palivizumab
    Paes, Bosco
    Saleem, Mahwesh
    Kim, Doyoung
    Lanctot, Krista L.
    Mitchell, Ian
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2019, 38 (08) : 1561 - 1568
  • [19] Prevention of respiratory syncytial virus infections in high-risk infantsby monoclonal antibody (palivizumab)
    Groothuis, JR
    Nishida, H
    PEDIATRICS INTERNATIONAL, 2002, 44 (03) : 235 - 241
  • [20] Regional impact of prophylaxis with the monoclonal antibody palivizumab on hospitalisations for respiratory syncytial virus in infants
    Duppenthaler, A
    Gorgievski-Hrisobo, M
    Aebi, C
    SWISS MEDICAL WEEKLY, 2001, 131 (11-12) : 146 - 151
12345